20% of Antibodies not specific?

  • Thread starter Thread starter gravenewworld
  • Start date Start date
  • Tags Tags
    Antibodies Specific
Click For Summary

Discussion Overview

The discussion revolves around the validation of antibodies in academic versus industrial settings, particularly focusing on the prevalence of non-specific binding and the implications for scientific research. Participants explore the reliability of commercial antibodies and the necessity of validation in various applications, including immunofluorescence and Western blotting.

Discussion Character

  • Debate/contested
  • Technical explanation
  • Conceptual clarification

Main Points Raised

  • One participant criticizes the academic community for not validating antibodies as rigorously as industry does, suggesting that this leads to poor scientific practices.
  • Another participant counters that they personally validate their antibodies and challenges the claim that no one in academia validates reagents.
  • A third participant questions the interpretation of a cited paper, suggesting it focuses on validating a method rather than reagents like antibodies.
  • Some participants express skepticism about the cited paper's effectiveness, noting potential issues with knockdown efficiency and off-target effects in siRNA studies.
  • There is a discussion about the varying effectiveness of antibodies across different applications, with some arguing that antibodies that fail in one context may still be useful in another.
  • Concerns are raised regarding the necessity of negative controls to account for non-specific binding in experiments.

Areas of Agreement / Disagreement

Participants express differing views on the validation practices in academia versus industry, with no consensus reached on the adequacy of current validation methods or the implications of non-specific binding in antibody use.

Contextual Notes

Some participants highlight the variability of antibody performance across different experimental systems and applications, indicating that validation may depend on specific contexts and protocols.

gravenewworld
Messages
1,129
Reaction score
27
Nice little paper about properly validating your reagents:

http://www.ncbi.nlm.nih.gov/pubmed/22361696Why is it in academia absolutely no one validates their reagents like antibodies while in industry it is absolutely required?

Rather than admitting their results are due to nonspecific binding, I've seen some papers where academics attribute their results to say something like another unknown isoform of the protein that they're studying.

Why is it that the peer review system has completely and utterly failed to to address this type of terrible science? What's worse is that once results that come from an antibody that might not be specific is published, many other labs go out and start using the same antibody to study the protein(s) in question.

What a complete an utter joke a lot of science being done now has become. Manufacturers are notorious for being lazy when it comes to validating their antibodies, academics simply take it for granted that they are supposed to work. Maybe it is time our universities do high quality science with validation like industry?
 
Biology news on Phys.org
I always validate my antibodies and indeed I've found many commercial antibodies to be non-specific. I don't recognize your statement that in academia no one validates their reagents. What I wonder is whether the paper you cite has validated the specificity of the siRNA :biggrin:
 
gravenewworld said:
Nice little paper about properly validating your reagents:

http://www.ncbi.nlm.nih.gov/pubmed/22361696

<snip>

I won't have access to the full article until Tuesday (access thru work), but based on the abstract, I don't understand why you say the article concerns validation of reagents. I read the abstract as validation of a method to measure the spatial distribution of expressed proteins by siRNA (alternatively, validation of the siRNA method as per Monique).

Why do you say "validates their reagents like antibodies"?
 
I don't find the paper impressive and they appear to ignore the fact that knockdown might not be efficient or has off-target effects. The idea to use siRNA to verify protein localization is not new.

gravenewworld said:
Why is it in academia absolutely no one validates their reagents like antibodies while in industry it is absolutely required?

The statement that absolutely no one validates their reagents is ridiculous, it makes me wonder what field you are into have such a view. The statement that in industry the validation is absolutely required is not valid either since I mentioned that commercial antibodies can also be a-specific. I would applaud it if these antibody selling companies would validate their products.
 
To play Devil's advocate, there are other uses for antibodies than immunofluoresence and often the antibodies that work well for immunofluorescence do not work well for these other applications (such as Western blotting). So, these 20% of commercially available antibodies that don't seem to work well aren't necessarily worthless (although from experience, I've come across plenty of commercially available antibodies that don't seem to work well for any purpose).
 
Ygggdrasil said:
To play Devil's advocate, there are other uses for antibodies than immunofluoresence and often the antibodies that work well for immunofluorescence do not work well for these other applications (such as Western blotting). So, these 20% of commercially available antibodies that don't seem to work well aren't necessarily worthless (although from experience, I've come across plenty of commercially available antibodies that don't seem to work well for any purpose).

Sure- most manufacturers even suggest 'optimal' applications (for primary antibodies: ELISA, WB, IP, IF, etc.), see http://igene.invitrogen.com/isearch/antibody.do

It's also true that *negative* controls should *always* be performed to check against non-specific binding (for example). Lastly, since experimental systems vary so widely all protocols: immunohistochemistry, siRNA, transfection, etc, must be carefully optimized: what works on one cell type may not work on another.

The OP did not understand the content of the linked article.
 

Similar threads

  • · Replies 2 ·
Replies
2
Views
2K
  • · Replies 93 ·
4
Replies
93
Views
18K
  • · Replies 15 ·
Replies
15
Views
2K
  • · Replies 27 ·
Replies
27
Views
4K
  • · Replies 2 ·
Replies
2
Views
2K
  • · Replies 6 ·
Replies
6
Views
3K
  • · Replies 3 ·
Replies
3
Views
3K
  • · Replies 8 ·
Replies
8
Views
3K
  • · Replies 1 ·
Replies
1
Views
3K
  • · Replies 4 ·
Replies
4
Views
3K